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Abstract
The goal of this work was to study the efficacy of the positron emission tomography (PET) tracers 2-deoxy-2-[18F]fluoro-D-glucose ([18F]
FDG) and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]ATSM) and in monitoring placental and fetal functional response to
acute hyperoxia in late-term pregnant mice subjected to experimentally induced chronic hypoxia. E15 mice were maintained at 12%
inspired oxygen for 72 hours and then imaged during oxygen inhalation with either [18F]FDG to monitor nutrient transport or 64Cu-
ATSM to establish the presence of hypoxia. Computed tomography (CT) with contrast allowed clear visualization of both placentas and
fetuses. The average ratio of fetal to placental [18F]FDG uptake was 0.45 ± 0.1 for the hypoxic animals and 0.55 ± 0.1 for the normoxic
animals, demonstrating a significant decrease (p = .0002) in placental function in dams exposed to chronic hypoxic conditions. Hypoxic
placentas and fetuses retained more 64Cu-ATSM compared to normoxic placentas and fetuses. Herein we report first-in-mouse PET
imaging of fetuses employing both tracers [18F]FDG (metabolism) and 64Cu-ATSM (hypoxia). [18F]FDG PET/CT imaging allowed clear
visualization of placental-fetal structures and supported quantification of tracer uptake, making this a sensitive tool for monitoring
placental function in preclinical rodentmodels. Thesemeasurements illustrate the potentially irreversible damage generated by chronic
exposure to hypoxia, which cannot be corrected by acute exposure to hyperoxia.
T HE PLACENTA MAINTAINS dynamic fetal home-ostasis by performing a wide range of physiologic
functions, which, after birth, are carried out by multiple
organs, such as the kidney, liver, gastrointestinal tract, lungs,
and endocrine glands. The primary functions of the placenta
are to mediate the transfer of respiratory gases, water, ions,
and nutrients; provide an immunologic barrier between
fetus and mother; and produce and secrete a vast array of
hormones, cytokines, and signaling molecules. Malforma-
tions in the structure or function of the placenta, the uterus,
or the connection between them can lead to life-threatening
sequelae for the mother and progeny.1,2 Maternal and fetal
blood flow within the placenta and exchange of nutrients
and oxygen between the two vascular systems are essential
aspects of placenta-fetal units. Insufficiencies in these func-
tions may result in a variety of severe prenatal and postnatal
syndromes, including intrauterine growth restriction
(IUGR), preeclampsia, and fetal death in utero, as well as a
predisposition to systemic cardiovascular and pulmonary
vascular dysfunction.3–6 Furthermore, increasing epide-
miologic evidence has demonstrated that aberrant placental
function during fetal development can have long-term
negative impacts on human adult health, including increased
risk of ischemic heart disease.7,8 Acute administration of
oxygen is frequently used to reduce fetal hypoxic stress in
pregnant women.
Characterizing placental function is vital for under-
standing fetal physiology, growth patterns, and complica-
tions during pregnancy. Thus, understanding the factors
that affect transport across the placenta can impact both
broad areas of basic research and clinical practice. Non-
invasive imaging methods can play a key role in assessing
the efficiency and integrity of this transport function. A
wide variety of preclinical magnetic resonance imaging
(MRI) studies of placenta structure and function have been
described.9–13 By contrast, relatively few studies employing
radionuclides to study placenta have been reported.
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Although such experiments may not readily translate to
the clinic, they can provide valuable functional and
metabolic information in the preclinical setting. Recently,
several groups have developed nonhuman-primate animal
models for investigation of drug transfer from mother to
fetus.14–16 However, radionuclide-based studies employing
nonhuman primates are prohibitively expensive, and the
development of positron emission tomography (PET) in
small animal models of pregnancy could provide impor-
tant insights into placental function; however, relatively
few of these studies have been conducted.17,18 Herein we
report first-in-mouse PET studies employing the tracers
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) (metabolism)
and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-
ATSM) (hypoxia).
[18F]FDG PET has long been used to measure glucose
transport in many disease states and thus is an ideal tracer
for our proof-of-principle studies.19–23 The overarching goal
of our work is to enhance our knowledge of placental-fetal
transport of nutrients, in this case glucose, to provide a
better understanding of the unique properties of mamma-
lian reproduction. To this end, studies to assess the ability of
FDG PET to measure changes in placental function were
conducted in normal pregnant animals and pregnant mice
exposed to chronic hypoxic conditions. All mice were subject
to acute hyperoxia during FDG-PET imaging.
Materials and Methods
All animal experiments were conducted according to the
guidelines of the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health under a protocol
approved by the Washington University Animal Studies
Committee. Timed pregnant CD-1 (Crl:CD1(ICR))mice were
obtained from Charles River Laboratories (Wilmington, MA).
Hypoxia studies were conducted using a hypoxia cham-
ber (BioSpherix, Lacona, NY), as previously reported.24
Briefly, mice were fed a standard rodent chow and housed in
a 12:12-hour light-dark cycle in room air. The hypoxic
atmosphere was maintained at fraction of inspired oxygen
(FIO2) = 12% with a ProOx 110 gas oxygen controller
(BioSpherix). The hypoxic cohort was exposed to an
atmosphere with FIO2 = 12% beginning on embryonic day
15 (E15) and maintained in a hypoxic environment for 72
hours. Mice were imaged immediately following hypoxic
exposure.
Radiochemistry
[18F]FDG was produced on a GE Fastlab and 64Cu was
produced on a CS-15 biomedical cyclotron, both in the
Washington University Cyclotron Facility.25,26 64Cu-
ATSM was prepared according to previously published
methods.26,27
Small Animal PET/Computed Tomography
Prior to imaging, animals were anesthetized with 2% iso-
flurane in either oxygen (FDG study) or air (64Cu-ATSM
study) and the tail vein was catheterized using 0.025 OD 
0.012 ID Micro-Renathane tubing (Braintree Scientific,
Braintree, MA) attached to a heparinized 0.3 cc, 29-gauge,
half-inch insulin syringe filled with saline. One hundred
microcuries of either [18F]FDG (hypoxic n = 6, normoxic
n = 3) or 64Cu-ATSM (hypoxic n = 4, normoxic n = 4) was
then injected coincidentally with the start of the PET scan-
ning. Dynamic PET images were acquired for 60 minutes.
The PET study was followed by the injection of 3.5 mgI/g
of body weight Omnipaque (iohexol, 350 mgI/mL, GE
Healthcare, Princeton, NJ) equivalent to a dose of
0.028 mmol/kg inorganic iodine through the tail-vein
catheter, coincidental with the initiation of 6-minute com-
puted tomography (CT). PET data were reconstructed using
standard methods with the maximum a posteriori prob-
ability (MAP) algorithm. CT images were overlaid on the
PET images, and volumes of interest (VOI) were drawn
using CT anatomic guidelines. Additional details can be
found in the supplementary information (Figure S1 and
Figure S2, online version only).
Statistical Analysis
Data are expressed as mean ± SD unless noted otherwise.
Statistical significance was determined with an unpaired,
two-tailed Student t-test and 95% confidence level, and
p values less than .05 were considered significant. All data
were analyzed and plotted using GraphPad Prism version 6.0
(GraphPad Software, La Jolla, CA).
Results and Discussion
To evaluate [18F]FDG as an imaging modality for studying
placental function, we investigated the effect of chronic
hypoxia on maternal-fetal glucose transport. E15.5 mice
were exposed to a hypoxic environment for 72 hours and
imaged at E18.5 with [18F]FDG as described in the Methods
section. To achieve the contrast needed for the anatomically
guided structure determination, Omnipaque, an iodine-
based CT contrast agent, was used, as described in Methods.
Imaging with CT contrast allowed clear visualization of
placentas and fetuses, as demonstrated by coregistered
PET/CT axial, coronal, and sagittal projections (Figure 1,
A and B). Time-activity curves (TACs) obtained from the
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VOI analysis showed a rapid uptake of [18F]FDG and slow
washout in normoxic and hypoxic animals (Figure 1,
C and D). To investigate the efficiency of the nutrient
transfer from placenta to fetus, the ratios of fetal-
to-placental dynamic [18F]FDG uptake were calculated from
the TAC data collected between 10 and 60 minutes following
tracer injection. A comparison of the ratios of fetal to pla-
cental FDG uptake showed a significant decrease (p = .0002)
in placental function in dams exposed to hypoxic conditions
(Figure 2A). The average ratio between fetuses and placentas
for the hypoxic animals was 0.44 ± 0.1 (n = 42), whereas the
normoxic animals demonstrated a ratio of 0.55± 0.1 (n = 25).
The mean [18F]FDG uptake by hypoxic and normoxic pla-
centas and fetuses is compared in Figure 2B. [18F]FDG
uptake was significantly higher in the fetuses and placentas
of normoxic animals (p = .0001 for both pairs), suggesting a
transfer defect in hypoxic animals due to the chronic hypoxic
injury, which is not corrected by acute hyperoxia (Table 1).
Interestingly, there was no significant difference in mean
tracer uptake between the hypoxic placentas and fetuses
(p = .059). Overall, [18F]FDG PET demonstrated the
robustness required to detect small differences in placental-
fetal nutrient transfer.
To evaluate the exposure to chronic tissue hypoxia,
hypoxia-challenged animals and normoxic animals were
imaged during normal air inhalation using 64Cu-ATSM, a
tracer that is specifically retained in tissues with low O2
tension.28–30 Systemic chronic hypoxia was induced for
72 hours as described in Methods. After injecting 100 mCi of
64Cu-ATSM, dynamic disintegration data were collected for
30 minutes. A comparison of 64Cu-ATSM retention in the
tissues of animals exposed to systemic chronic hypoxia or
normoxia showed significantly more 64Cu-ATSM associated
with hypoxic tissues (Figure 3A, p = .033). The mean uptake
of 64Cu-ATSM in hypoxic maternal tissue (muscle) was
32,500 ± 6,300 Bq/mL, whereas the normoxic muscle tissue
retained an average of 15,800 ± 6,600 Bq/mL. Similar to
[18F]FDG uptake, there was no significant difference in 64Cu-
ATSM uptake among maternal tissues, fetuses, or placentas of
hypoxic animals (Figure 3B). As shown in Figure 3C, the
A B
C D
Figure 1. [18F]FDG PET/CT imag-
ing of glucose transport. [18F]FDG
PET/CT images (A and B) and time-
activity curves (C and D) for E18.5
normoxic (A and C) and hypoxic (B
and D) mice. F = fetus; P = placenta.
A B
Figure 2. [18F]FDG fetal placental ratios as a measurement of placental function. A, Average ratio of fetal-to-placental uptake of [18F]FDG in
hypoxic and normoxic animals. B, Mean [18F]FDG uptake in fetuses and placentas of hypoxic and normoxic animals.
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mean 64Cu-ATSMuptake in hypoxic (45,400± 17,100 Bq/mL,
n = 37) and normoxic (28,600 ± 16,200 Bq/mL, n = 26)
placentas (Figure 3C) was significantly different (p = .0002).
A similar difference was observed when comparing the
fetuses of hypoxic (31,700 ± 24,600 Bq/mL, n = 37) and
normoxic (15,800 ± 5,600 Bq/mL, n = 26) animals, where
p = .002 (Figure 3D). These data indicate the persistence of
chronic hypoxia and suggest that the observed [18F]FDG
transfer defect may be due to tissue injury resulting from
chronic hypoxia. Further studies are required to determine if
this effect is entirely irreversible.
PET was used in earlier studies of maternal-to-fetal
transfer in large animals, such as sheep31 and nonhuman
primates.32,33 Benveniste and colleagues used [18F]FDG
PET and MRI to monitor the movement of labeled com-
pounds across placenta and their trafficking within the fetal
tissues in healthy Macaca radiata.15 In a similar study in
sheep under conditions of acute hypoxia performed by
Tchirikov and colleagues, the investigators observed a
decrease in fetal organ perfusion, whereas glucose uptake by
the fetus was unaffected.31 Although expensive and logis-
tically complicated, these studies were instrumental in
motivating the use of PET for investigating placental-fetal
trafficking in preclinical models. Moreover, a broad range of
experimental disease states, both acute and chronic, are
available in small rodents, enabling a variety of studies of
gestational pathologies and their effect on placental-fetal
transfer.
In this work, we showed that excellent coregistration of
PET and contrast-enhanced CT data could be achieved.
However, due to the limitations in spatial resolution of the
small animal PET scanner, accumulation of the labeled
compound in specific fetal organs could not be determined.
Nonetheless, [18F]FDG PET could detect small differences in
tracer transfer caused by an experimentally induced
pathology that was corroborated by an independent PET
tracer. Overall, the use of PET/CT in small animal systems to
track placental-fetal transport of a wide range of labeled
compounds in normal and/or disease states could lead to a
better understanding of prenatal pathologies.
Conclusions
[18F]FDG PET imaging was used to monitor the effects of
chronic systemic hypoxia in a late-term murine pregnancy
A B
C D
Figure 3. 64Cu-ATSM imaging of hypoxia. A, Mean 64Cu-ATSM retention in maternal muscle tissue (thigh) of hypoxic and normoxic animals.
B, Mean 64Cu-ATSM retention in maternal muscle, placentas, and fetuses of hypoxic animals. Mean 64Cu-ATSM retention in (C) placentas and
(D) fetuses of hypoxic and normoxic animals.
Table 1. One Way Anova Multiple Comparison
Group Summary
Adjusted
p value
Hypoxic placenta vs. hypoxic fetus not supplied .0586
Hypoxic placenta vs. normoxic placenta **** < .0001
Hypoxic fetus vs. normoxic fetus ** .0072
Normoxic placenta vs. normoxic fetus **** < .0001
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model. [18F]FDG PET images provided the high image
contrast and spatial resolution required for accurate
quantification of tracer distribution between placenta and
fetus, demonstrating that [18F]FDG PET is a sensitive tool
for monitoring placental function in preclinical mouse
models.
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Figure S1. PET/CT maximum intensity projection images of animals
injected with 64Cu-ATSM. F = fetus; P = placenta.
A
B
Figure S2. CT image of an E18.5 mouse (A); CT image of an E18.5
mouse indicating region of interest used for quantification (B). F =
fetus; P = placenta.
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